Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion

Announcement follows several years of stellar growth and points to a sharper focus on expanding commercial NCE opportunities

Hyderabad, India, April 01, 2026: Neuland Laboratories [NLL] (NSE: NEULANDLAB; BSE:524558), a global contract development and manufacturing organization (CDMO) specialising in complex APIs, has today announced a leadership change. Saharsh Davuluri will assume the role of Chief Executive Officer and Managing Director, effective immediately, as the company moves into its next stage of CDMO growth.

Saharsh has been with the company for more than 18 years and will position the CDMO as a premier global API process development and commercial manufacturing specialist. Neuland's recent successes have been built on a growing reputation for scale-up of complex APIs and peptides, and the business has tripled its contract services revenues during the last 3-years.

Saharsh has led Neuland's transformation into a new chemical entity (NCE)-focused drug substance CDMO. In recent years, the company has secured a growing number of commercial manufacturing contracts with global innovator companies, reflecting rising demand for its strengths in process chemistry, scale-up, and reliable commercial supply.

Saharsh succeeds Sucheth Davuluri, who has played a key role in the Company's transformation towards a CDMO-focused business model and will now assume the role of Executive Vice Chairman of the Company.

"It's an incredibly exciting time for the wider CDMO sector, and for Neuland in particular, as global innovators increasingly come to us with their most complex chemistries and scale-up challenges. But we have not rested on these successes, and I will now be looking to further accelerate this growth transformation over the next five years. We have already committed to a four-phase expansion of commercial peptide capacity and are also doubling our process development capabilities," **commented Saharsh Davuluri**. He added, *"The secret sauce behind our recent commercial success, however, has been our incredibly strong reputation for specialist process chemistries, accelerated development timelines and, of course, consistent commercial supply. Building scale is important, but our team's reputation as problem solvers and process innovators, coupled with consistent CMC delivery, is the real driver behind our rapidly growing number of biotech and big pharma partners."*

Neuland is embarking on an aggressive expansion phase and could, pending customer approvals, secure several more commercial NCE contracts [including peptides] over the next one to two years.

The CDMO operates three US FDA-inspected manufacturing facilities and a 40,000 sq. ft. R&D facility, with 1218 KL of installed capacity and more than 20 commercial contracts across APIs and intermediates. The company's recent growth has been supported by its ability to accelerate development timelines through parallel development strategies, while maintaining a strong regulatory track record across 18 US FDA inspections

Saharsh added: *"We see immediate opportunities for commercial contract growth, particularly in areas such as peptides, but our CDMO investment approach is built around the innovation pipelines of our customers. So, we continue to structure our teams and capabilities to meet the evolving development needs of our partners.*
"That means investing not just for near-term demand, but for the medium and long term. Our ambition is to become one of the world's top five API-focused CDMOs over the next decade."

About Neuland Labs

Neuland Laboratories Limited [Neuland] is a specialist API CDMO partner for big pharma and biotech – delivering world-class process development and commercial supply services for the most complex molecules and New Chemical Entities. Serving clients in over 80 countries, Neuland operates three US FDA and EU GMP-compliant facilities in India, with a combined reactor capacity of approximately 1218kL. The CDMO invested in a new commercial scale peptide facility in 2026, and is opening a large, dedicated R&D process development centre in Hyderabad.

Neuland is listed on the NSE (NEULANDLAB) and BSE (524558) in India. The company has filed over 1000 DMFs globally – as it also supports generic drug substance providers – and offers more than 100 APIs across multiple therapeutic areas

*Disclaimer: This press release may contain certain **forward-looking statements**, including statements regarding business strategy, future operations, growth plans, expansion initiatives, and leadership priorities. These statements are based on management's current expectations and assumptions and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied.*